This company has been marked as potentially delisted and may not be actively trading. NASDAQ:INTS Intensity Therapeutics (INTS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsCompetitorsEarningsFDA EventsHeadlinesOwnershipShort InterestTrendsBuy This Stock About Intensity Therapeutics Stock (NASDAQ:INTS) 30 days 90 days 365 days Advanced Chart Get Intensity Therapeutics alerts:Sign Up Key Stats Today's Range$2.36▼$2.7950-Day Range N/A52-Week Range$0.26▼$5.09Volume73,559 shsAverage Volume473,117 shsMarket Capitalization$8.40 millionP/E RatioN/ADividend YieldN/APrice Target$6.75Consensus RatingModerate Buy Company Overview Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut. Read More Intensity Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreINTS MarketRank™: Intensity Therapeutics scored higher than 50% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingIntensity Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageIntensity Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Intensity Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intensity Therapeutics are expected to grow in the coming year, from ($1.18) to ($1.00) per share.Price to Book Value per Share RatioIntensity Therapeutics has a P/B Ratio of 1.76. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.94% of the float of Intensity Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics has recently decreased by 37.42%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntensity Therapeutics does not currently pay a dividend.Dividend GrowthIntensity Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted2.94% of the float of Intensity Therapeutics has been sold short.Short Interest Ratio / Days to CoverIntensity Therapeutics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Intensity Therapeutics has recently decreased by 37.42%, indicating that investor sentiment is improving significantly. News and Social Media1.1 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Intensity Therapeutics this week, compared to 0 articles on an average week.Search Interest7 people have searched for INTS on MarketBeat in the last 30 days. This is an increase of 600% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intensity Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.10% of the stock of Intensity Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 3.74% of the stock of Intensity Therapeutics is held by institutions.Read more about Intensity Therapeutics' insider trading history. Receive INTS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intensity Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address INTS Stock News HeadlinesIntensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve ...July 2, 2025 | finanznachrichten.deIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST) - Seeking AlphaJuly 2, 2025 | seekingalpha.comForget Nvidia, This “Ghost Town” Company Holds the Key to the AI BoomCold War Discovery Could Unlock $100 Trillion in Wealth Jeff recently traveled to an American ghost town to investigate this crazy Cold War story… Because it could hold the key to the entire $100 trillion AI boom. It involves an American ghost town with just 30 people… And a new twist to the AI boom that could make a lot of people rich. | Brownstone Research (Ad)Intensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)June 30, 2025 | prnewswire.comINTS - Intensity Therapeutics Inc Valuation - MorningstarJune 27, 2025 | morningstar.comMIntensity Therapeutics announces public offering of common stockJune 13, 2025 | investing.comIntensity Therapeutics, Inc. Announces Pricing of Public OfferingJune 11, 2025 | prnewswire.comIntensity Therapeutics, Inc. Announces Proposed Public Offering of Common StockJune 11, 2025 | prnewswire.comSee More Headlines INTS Stock Analysis - Frequently Asked Questions How were Intensity Therapeutics' earnings last quarter? Intensity Therapeutics Inc. (NASDAQ:INTS) released its quarterly earnings data on Tuesday, May, 13th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.21) by $0.01. When did Intensity Therapeutics IPO? Intensity Therapeutics (INTS) raised $20 million in an initial public offering on Friday, June 30th 2023. The company issued 3,900,000 shares at $5.00 per share. What other stocks do shareholders of Intensity Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intensity Therapeutics investors own include Amgen (AMGN), Costco Wholesale (COST), Cisco Systems (CSCO), Honeywell International (HON), Intel (INTC), Intuitive Surgical (ISRG) and Mondelez International (MDLZ). Company Calendar Last Earnings5/13/2025Today7/11/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED-BIOMED/GENE Sub-IndustryN/A Current SymbolNASDAQ:INTS CIK1567264 Webwww.intensitytherapeutics.com Phone203 221 7381FaxN/AEmployees2,021Year FoundedN/APrice Target and Rating Average Price Target for Intensity Therapeutics$6.75 High Price Target$8.50 Low Price Target$5.00 Potential Upside/Downside+1,914.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$16.27 million Net MarginsN/A Pretax MarginN/A Return on Equity-527.85% Return on Assets-276.29% Debt Debt-to-Equity Ratio0.31 Current Ratio0.63 Quick Ratio0.63 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.19 per share Price / Book1.76Miscellaneous Outstanding Shares25,070,000Free Float20,786,000Market Cap$8.40 million OptionableNot Optionable Beta3.27 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:INTS) was last updated on 7/12/2025 by MarketBeat.com Staff From Our Partners3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe End of Elon Musk…?The End of Elon Musk? Don't make him laugh. Jeff Brown has been hearing this same tired story for years, an...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | SponsoredTrump’s whole-government AI plans leakedThe New Elon Musk is officially stepping back from his day-to-day duties with DOGE. At least, that's the s...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intensity Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intensity Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.